期刊
PROTEOMICS CLINICAL APPLICATIONS
卷 2, 期 4, 页码 543-555出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/prca.200780159
关键词
biomarker; expressed prostatic secretions; mass spectrometry; prostate cancer
资金
- NCI NIH HHS [U54 CA119347-050001, U54 CA119347-059005, U54 CA119347-040001, U54 CA119347-049005, U54 CA119347] Funding Source: Medline
- NIGMS NIH HHS [P50 GM076547-01, P50 GM076547] Funding Source: Medline
Expressed prostatic secretions (EPS) contain proteins of prostate origin that may reflect the health status of the prostate and be used as diagnostic markers for prostate diseases including prostatitis, benign prostatic hyperplasia, and prostate cancer. Despite their importance and potential applications, a complete catalog of EPS proteins is not yet available. We, therefore, undertook a comprehensive analysis of the EPS proteome using 2-D micro-LC combined with MS/MS. Using stringent filtering criteria, we identified a list of 114 proteins with at least two unique-peptide hits and an additional 75 proteins with only a single unique-peptide hit. The proteins identified include kallikrein 2 (KLK2), KLK3 (prostate-specific antigen), KLK11, and nine cluster of differentiation (CD) molecules including CD10, CD13, CD14, CD26, CD66a, CD66c, CD 143, CD177, and CD224. To our knowledge, this list represents the first comprehensive characterization of the EPS proteome, and it provides a candidate biomarker list for targeted quantitative proteornics analysis using a multiple reaction monitoring (MRM) approach. To help prioritize candidate biomarkers, we constructed a protein-protein interaction network of the EPS proteins using Cytoscape (www.cytoscape.org), and overlaid the expression level changes from the Oncomine database onto the network.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据